Estimates have moved into the negative territory after ugly second-quarter results, sending Syneron (ELOS) to a Zacks Rank No. 5 (Strong Sell) last month.
About the Company
Syneron is a leading global aesthetic device company with a 29% worldwide market share. It focuses on non-invasive aesthetic procedures and operates in two segments: Professional Aesthetic Devices and Emerging Business Units. The ccompany provides advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, improving the skin's appearance, and the treatment of acne, leg veins, and cellulite. The company sells its products under two distinct brands, Syneron and Candela.
ELOS reported its second-quarter FY 2013 results on Aug. 14, 2013. Revenues in Q2 2013 were $68.8 million, up 1% from $68.1 million in the second quarter of 2012. Net operating loss for the quarter was $0.01 per share, substantially worse than the Zacks Consensus Estimate of earnings of $0.03 per share. Gross margin for the quarter was 48.3%, down from 53.2% in second quarter of 2012. Revenue mix, increased production costs, and volume discounts affected the gross margin.
Due to disappointing results, quarterly and annual estimates have been revised sharply downward in the past few weeks. Zacks consensus estimates for the current quarter and year are now in negative territory -- ($0.05) and ($0.19) per share, respectively, down substantially from $0.03 and $0.14 per share, respectively, 60 days ago.
The Bottom Line
ELOS seems to be undergoing a management transition with a new CEO earlier this year and a new head of North American sales announced at the time of the second-quarter results. The results of these management changes remain to be seen. Furthermore, while the company is well-positioned in high-growth geographies, which are witnessing a strong shift toward non-invasive procedures, recent sales force initiatives may take some time to pay off.
ELOS is now a Zacks Rank No. 4 (Sell) stock, and it has a longer-term recommendation of "Underperform." Furthermore, its Zacks Industry Rank of 198 out of 265 also indicates some weakness in the short to mid-term. As such, investors would like to avoid this stock for the time being.
Syneron: Free Stock Analysis Report (email registration required)